Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GGT1 | P19440 | 1/20 | 0.52 |
| ▸ | ARG1 | P05089 | 1/20 | 0.47 |
| ▸ | ARG2 | P78540 | 1/20 | 0.47 |
| ▸ | NOS2 | P35228 | 5/20 | 0.41 |
| ▸ | NOS1 | P29475 | 3/20 | 0.41 |
| ▸ | NOS3 | P29474 | 1/20 | 0.41 |
| ▸ | BLM | P54132 | 2/20 | 0.37 |
| ▸ | RNPEP | Q9H4A4 | 1/20 | 0.34 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.34 |
| ▸ | MEN1 | O00255 | 2/20 | 0.34 |
| ▸ | CYP1A2 | P05177 | 2/20 | 0.34 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.34 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.34 |
| ▸ | USP2 | O75604 | 1/20 | 0.34 |
| ▸ | EGFR | P00533 | 1/20 | 0.34 |
| ▸ | FYN | P06241 | 1/20 | 0.34 |
| ▸ | POLB | P06746 | 1/20 | 0.34 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.34 |
| ▸ | GAA | P10253 | 1/20 | 0.34 |
| ▸ | MAPT | P10636 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL243496 | 1.00 | GGT1 (0.52) | GGT1ARG1ARG2NOS2NOS1 | |
| SCHEMBL5614525 | 1.00 | GGT1 (0.52) | GGT1ARG1ARG2NOS2NOS1 | |
| SCHEMBL162014 | 1.00 | GGT1 (0.52) | GGT1ARG1ARG2NOS2NOS1 | |
| SCHEMBL5614536 | 1.00 | GGT1 (0.52) | GGT1ARG1ARG2NOS2NOS1 | |
| Hydrochloric Acid SCHEMBL13585526 | 0.98 | GGT1 (0.50) | GGT1ARG1ARG2NOS2NOS1 | |
| SCHEMBL4263059 | 0.90 | GGT1 (0.44) | GGT1ARG1ARG2NOS2NOS1 | |
| SCHEMBL29054949 | 0.89 | GGT1 (0.43) | GGT1ARG1ARG2NOS2NOS1 | |
| SCHEMBL2720103 | 0.89 | ARG1 (0.47) | GGT1ARG1ARG2NOS2NOS1 | |
| SCHEMBL11192504 | 0.82 | NOS1 (0.33) | GGT1ARG1ARG2NOS2NOS1 | |
| SCHEMBL8687592 | 0.80 | GGT1 (0.65) | GGT1ARG1ARG2NOS2NOS1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1811 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090215895-A1 | Therapeutic and carrier molecules | PEPLIN BIOLIPIDS PTY LTD (AU) | 2009-08-27 | — | — | US | claimed |
| EP-1718602-A4 | THERAPEUTIC AND CARRIER MOLECULES | PEPLIN BIOLIPIDS PTY LTD (AU) | 2007-12-12 | — | — | EP | claimed |
| US-7256172-B1 | Method of treatment and agents useful for same | THE UNIVERSITY OF MELBOURNE (AU) | 2007-08-14 | — | — | US | claimed |
| EP-1718602-A1 | THERAPEUTIC AND CARRIER MOLECULES | Peplin Biolipids Pty Ltd. (AU) | 2006-11-08 | — | — | EP | claimed |
| US-7070969-B1 | Plasmin inhibitors from the australian brown snake Pseudonaja textilis textilis | THE UNIVERSITY OF QUEENSLAND (AU) | 2006-07-04 | — | — | US | claimed |
| WO-2005073164-A1 | THERAPEUTIC AND CARRIER MOLECULES | PEPLIN BIOLIPIDS PTY LTD (AU) | 2005-08-11 | — | — | WO | claimed |
| WO-2026085582-A1 | PROTEIN CAGES | THE UNIVERSITY OF SYDNEY (AU) | 2026-04-30 | — | — | WO | disclosed |
| US-20260069728-A1 | MULTI-TARGETING COMPOUND AND USE THEREOF | CHENGDU SHETAI MEDICAL TECHNOLOGY CO., LTD. (CN) | 2026-03-12 | — | — | US | disclosed |
| US-20250319054-A1 | Synthetic Eicosanoid Analogues for the Treatment and Prevention of Diseases Associated with Increased GDF15 Plasma Concentration | OMEICOS THERAPEUTICS GMBH (DE) | 2025-10-16 | — | — | US | disclosed |
| EP-4627079-A2 | THERMOSTABLE BINDING SCAFFOLDS | Nectagen, Inc. (US) | 2025-10-08 | — | — | EP | disclosed |
| US-20250263393-A1 | FAP INHIBITORS | SHANGHAI SINOTAU BIOTECH. CO., LTD (CN) | 2025-08-21 | — | — | US | disclosed |
| EP-4590664-A1 | INHIBITORS OF PROSTATE SPECIFIC MEMBRANE ANTIGEN AND USE THEREOF | Shanghai Sinotau Biotech. Co., Ltd (CN) | 2025-07-30 | — | — | EP | disclosed |
| US-12370158-B2 | Analogs of CYP-eicosanoids for use in treating or preventing a disorder associated with neovascularization and/or inflammation | OMEICOS THERAPEUTICS GMBH (DE) | 2025-07-29 | — | — | US | disclosed |
| WO-1994028014-A2 | PEPTIDE INHIBITORS OF UROKINASE RECEPTOR ACTIVITY | CHIRON CORPORATION (US) | 1994-12-08 | — | — | WO | disclosed |
| EP-0618221-A2 | Heterocyclic inhibitors of farnesyl protein transferase | BRISTOL-MYERS SQUIBB COMPANY (US) | 1994-10-05 | — | — | EP | disclosed |
| WO-1994011388-A1 | SUPPORT FOR THE SYNTHESIS OF MODULAR POLYMERS | CHIRON MIMOTOPES PTY. LTD. (AU) | 1994-05-26 | — | — | WO | disclosed |
| WO-1994003483-A1 | ENDOTHELIN RECEPTOR-BINDING COMPOUNDS | CHIRON CORPORATION (US) | 1994-02-17 | — | — | WO | disclosed |
| EP-0137351-B1 | Process for the enantioselective préparation of acyclic alpha-alkylated alpha-aminecarboxylic acids | Degussa Aktiengesellschaft (DE) | 1987-03-04 | — | — | EP | disclosed |
| US-4585892-A | Process for the enantioselective production of α-alkylated, acyclic α-aminocarboxylic acids | DEGUSSA AKTIENGESELLSCHAFT (DE) | 1986-04-29 | — | — | US | disclosed |
| EP-0137351-A2 | Process for the enantioselective préparation of acyclic alpha-alkylated alpha-aminecarboxylic acids | Degussa Aktiengesellschaft (DE) | 1985-04-17 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090215895-A1 | Therapeutic and carrier molecules | PHKG1, PHKG2, DGKB | GGT1 1211/4885ARG1 4434/4885ARG2 2829/4885 |
| US-20250319054-A1 | Synthetic Eicosanoid Analogues for the Treatment and Prevention of Diseases Associated with Increased GDF15 Plasma Concentration | IL15, ALOX15, FABP3 | GGT1 426/4885ARG1 262/4885ARG2 452/4885 |
| US-20260069728-A1 | MULTI-TARGETING COMPOUND AND USE THEREOF | CXCR4, CXCR2, GRPR | GGT1 1741/4885ARG1 747/4885ARG2 1804/4885 |
| US-20250263393-A1 | FAP INHIBITORS | FAP, APC, FIBP | GGT1 542/4885ARG1 2989/4885ARG2 4250/4885 |
| US-12370158-B2 | Analogs of CYP-eicosanoids for use in treating or preventing a disorder associated with neovascularization and/or inflammation | ALOX5, ALOX15B, ALOX15 | GGT1 550/4885ARG1 719/4885ARG2 516/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.